Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine

Authors

Deirdre K. Tobias, Brigham and Women's Hospital
Jordi Merino, Novo Nordisk Foundation Center for Basic Metabolic Research
Abrar Ahmad, Institutionen för Kliniska Vetenskaper, Malmö
Catherine Aiken, Rosie Hospital
Jamie L. Benham, Cumming School of Medicine
Dhanasekaran Bodhini, Madras Diabetes Research Foundation
Amy L. Clark, Saint Louis University School of Medicine
Kevin Colclough, University of Exeter Medical School
Rosa Corcoy, Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina
Sara J. Cromer, Massachusetts General Hospital
Daisy Duan, Johns Hopkins University School of Medicine
Jamie L. Felton, Indiana University School of Medicine
Ellen C. Francis, Rutgers School of Public Health
Pieter Gillard, KU Leuven– University Hospital Leuven
Véronique Gingras, University of Montreal
Romy Gaillard, Erasmus MC
Eram Haider, University of Dundee School of Medicine
Alice Hughes, University of Exeter Medical School
Jennifer M. Ikle, Stanford University School of Medicine
Laura M. Jacobsen, University of Florida
Anna R. Kahkoska, UNC Gillings School of Global Public Health
Jarno L.T. Kettunen, Helsinki University Hospital
Raymond J. Kreienkamp, Massachusetts General Hospital
Lee Ling Lim, Universiti Malaya
Jonna M.E. Männistö, Kuopio University Hospital
Robert Massey, University of Dundee School of Medicine
Niamh Maire Mclennan, Edinburgh Medical School
Rachel G. Miller, University of Pittsburgh Graduate School of Public Health
Mario Luca Morieri, Azienda Ospedale Università Padova
Jasper Most, Zuyderland
Rochelle N. Naylor, The University of Chicago
Bige Ozkan, Welch Center for Prevention Epidemiology and Clinical Research
Kashyap Amratlal Patel, University of Exeter Medical School
Scott J. Pilla, Johns Hopkins University School of Medicine

Document Type

Article

Publication Date

10-1-2023

Abstract

Precision medicine is part of the logical evolution of contemporary evidence-based medicine that seeks to reduce errors and optimize outcomes when making medical decisions and health recommendations. Diabetes affects hundreds of millions of people worldwide, many of whom will develop life-threatening complications and die prematurely. Precision medicine can potentially address this enormous problem by accounting for heterogeneity in the etiology, clinical presentation and pathogenesis of common forms of diabetes and risks of complications. This second international consensus report on precision diabetes medicine summarizes the findings from a systematic evidence review across the key pillars of precision medicine (prevention, diagnosis, treatment, prognosis) in four recognized forms of diabetes (monogenic, gestational, type 1, type 2). These reviews address key questions about the translation of precision medicine research into practice. Although not complete, owing to the vast literature on this topic, they revealed opportunities for the immediate or near-term clinical implementation of precision diabetes medicine; furthermore, we expose important gaps in knowledge, focusing on the need to obtain new clinically relevant evidence. Gaps include the need for common standards for clinical readiness, including consideration of cost-effectiveness, health equity, predictive accuracy, liability and accessibility. Key milestones are outlined for the broad clinical implementation of precision diabetes medicine.

This document is currently not available here.

Share

COinS